{
    "ticker": "CTNT",
    "name": "Cytosorbents Corporation",
    "description": "Cytosorbents Corporation is a critical care-focused medical technology company specializing in developing innovative blood purification therapies. Founded in 1998, the company is dedicated to improving patient outcomes in critical care settings through its flagship product, CytoSorb, a highly effective blood purification device designed to remove excess cytokines and toxins from the bloodstream during severe inflammatory conditions. This technology is particularly beneficial for patients suffering from sepsis, acute respiratory distress syndrome (ARDS), and other critical illnesses where cytokine storms play a detrimental role. Cytosorbents also focuses on expanding its product offerings to include additional therapies for kidney disease and other applications. The company operates on the principle that reducing harmful substances in the blood can significantly enhance recovery and survival rates. With a robust pipeline and ongoing clinical studies, Cytosorbents aims to establish itself as a leader in the field of blood purification and critical care treatment. The company\u2019s commitment to research and innovation is reflected in its collaborations with leading hospitals and research institutions worldwide, ensuring that it stays at the forefront of medical advancements.",
    "industry": [
        "Medical Devices",
        "Healthcare"
    ],
    "headquarters": "Monmouth Junction, New Jersey, USA",
    "founded": "1998",
    "website": "https://www.cytosorbents.com",
    "ceo": "Dr. Phillip Chan",
    "social_media": {
        "twitter": "https://twitter.com/Cytosorbents",
        "linkedin": "https://www.linkedin.com/company/cytosorbents/"
    },
    "investor_relations": "https://ir.cytosorbents.com",
    "key_executives": [
        {
            "name": "Dr. Phillip Chan",
            "position": "CEO"
        },
        {
            "name": "Michael M. E. D. K. K. Kim",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Blood Purification Devices",
            "products": [
                "CytoSorb"
            ]
        },
        {
            "category": "Therapies for Critical Care",
            "products": [
                "Kriya",
                "HemoDefend"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cytosorbents Corporation | Innovative Blood Purification Technologies",
        "meta_description": "Explore Cytosorbents Corporation, a leader in medical technology focused on blood purification therapies for critical care. Discover our products and commitment to improving patient outcomes.",
        "keywords": [
            "Cytosorbents",
            "Blood Purification",
            "CytoSorb",
            "Critical Care",
            "Medical Devices",
            "Sepsis"
        ]
    },
    "faq": [
        {
            "question": "What is Cytosorbents known for?",
            "answer": "Cytosorbents is known for its innovative blood purification therapies, particularly the CytoSorb device used in critical care settings."
        },
        {
            "question": "Who is the CEO of Cytosorbents?",
            "answer": "Dr. Phillip Chan is the CEO of Cytosorbents Corporation."
        },
        {
            "question": "Where is Cytosorbents headquartered?",
            "answer": "Cytosorbents is headquartered in Monmouth Junction, New Jersey, USA."
        },
        {
            "question": "What are Cytosorbents' main products?",
            "answer": "Cytosorbents' main products include the CytoSorb blood purification device and additional therapies such as Kriya and HemoDefend."
        },
        {
            "question": "When was Cytosorbents founded?",
            "answer": "Cytosorbents was founded in 1998."
        }
    ],
    "competitors": [
        "AVEO",
        "CRNX",
        "BLRX"
    ],
    "related_stocks": [
        "ABT",
        "MDT",
        "SYK",
        "BAX"
    ]
}